Enhanced expression of CD13 in vessels of inflammatory and neoplastic tissues

Journal of Histochemistry and Cytochemistry

Volumn 59, Issue 1, 2011, Pages 47-59

  Di Matteo, Paola ^a,b   Arrigoni, Gian Luigi ^c   Alberici, Luca ^a   Corti, Angelo ^c   Gallo Stampino, Corrado ^a   Traversari, Catia ^a   Doglioni, Claudio ^c   Rizzardi, Gian Paolo ^a  

^a MOLMED S P A   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

CD13 aminopeptidase N; Immunohistochemistry; NGR; Tumor; Vascular targeting

Indexed keywords

MICROSOMAL AMINOPEPTIDASE; MONOCLONAL ANTIBODY;

ANTIGEN EXPRESSION; ARTICLE; BLOOD VESSEL; BLOOD VESSEL DIAMETER; CANCER TISSUE; CAPILLARY; CONTROLLED STUDY; ENDOTHELIUM CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; PRIORITY JOURNAL; STROMA; TUMOR VASCULARIZATION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD13; BLOOD VESSELS; EPITHELIUM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; NEOPLASMS; PROTEIN TRANSPORT;

EID: 78650816301     PISSN: 00221554     EISSN: None     Source Type: Journal    
DOI: 10.1369/jhc.2010.956644     Document Type: Article

References (63)

1. Arap W, Kolonin MG, Trepel M, Lahdenranta J, Cardo-Vila M, Giordano RJ, Mintz PJ, Ardelt PU, Yao VJ, Vidal CI, et al. 2002. Steps toward mapping the human vasculature by phage display. Nat Med. 8:121-127.
2. Arap W, Pasqualini R, Ruoslahti E. 1998a. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 279:377-380.
3. Arap W, Pasqualini R, Ruoslahti E. 1998b. Chemotherapy targeted to tumor vasculature. Curr Opin Oncol. 10:560-565.
4. Ashmun RA, Look AT. 1990. Metalloprotease activity of CD13/ aminopeptidase N on the surface of human myeloid cells. Blood. 75:462-469.
5. Ashmun R, Shapiro LH, Look AT. 1992. Deletion of the zincbinding motif of CD13/aminopeptidase N molecules results in loss of epitopes that mediate binding of inhibitory antibodies. Blood. 79:3344-3349.
6. Atherton AJ, Monaghan P, Warburton MJ, Gusterson BA. 1992. Immunocytochemical localization of the ectoenzyme aminopeptidase N in the human breast. J Histochem Cytochem. 40:705-710.
7. Bauvois B. 2004. Transmembrane proteases in cell growth and invasion: new contributors to angiogenesis? Oncongene. 23:317-329.
8. Bauvois B, Dauzonne D. 2006. Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: chemistry, biological evaluations, and therapeutic prospects. Med Res Rev. 26:88-130.
9. Bhagwat SV, Lahdenranta J, Giordano R, Arap W, Pasqualini R, Shapiro LH. 2001. CD13/APN is activated by angiogenic signals and is essential for capillary tube formation. Blood. 97:652-659.
10. Bhagwat SV, Petrovic N, Okamoto Y, Shapiro LH. 2003. The angiogenic regulator CD13/APN is a transcriptional target of Ras signaling pathways in endothelial morphogenesis. Blood. 101:1818-1826.
11. Bogenrieder T, Finstad CL, Freeman RH, Papandreou CN, Scher HI, Albino AP, Reuter VE, Nanus DM. 1997. Expression and localization of aminopeptidase A, aminopeptidase N, and dipeptidyl peptidase IV in benign and malignant human prostate tissue. Prostate. 33:225-232.
12. Chen H, Kinzer CA, Paul WE. 1996. p161, a murine membrane protein expressed on mast cells and some macrophages, is mouse CD13/aminopeptidase N. J Immunol. 157:2593-2600.
13. Corti A. 2004. Strategies for improving the anti-neoplastic activity of TNF by tumor targeting. Methods Mol Med. 98:247-264.
14. Corti A, Ponzoni M. 2004. Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs. Ann N Y Acad Sci. 1028:104-112.
15. Curnis F, Arrigoni G, Sacchi A, Fischetti L, Arap W, Pasqualini R, Corti A. 2002. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res. 62:867-874.
16. Curnis F, Gasparri A, Sacchi A, Cattaneo A, Magni F, Corti A. 2005. Targeted delivery of IFNgamma to tumor vessels uncouples antitumor from counterregulatory mechanisms. Cancer Res. 65:2906-2913.
17. Curnis F, Sacchi A, Borgna L, Magni F, Gasparri A, Corti A. 2000. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol. 18:1185-1190.
18. Curnis F, Sacchi A, Corti A. 2002. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest. 110:475-482.
19. Dixon J, Kaklamanis L, Turley H, Hickson ID, Leek RD, Harris AL, Gatter KC. 1994. Expression of aminopeptidase-n (CD 13) in normal tissues and malignant neoplasms of epithelial and lymphoid origin. J Clin Pathol. 47:43-47.
20. Drexler HG. 1987. Classification of acute myeloid leukemias- a comparison of FAB and immunophenotyping. Leukemia. 1:697-705.
21. Ellerby HM, Arap W, Ellerby LM, Kain R, Andrusiak R, Rio GD, Krajewski S, Lombardo CR, Rao R, Ruoslahti E, et al. 1999. Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med. 5:1032-1038.
22. Enomoto K, Nishikawa Y, Omori Y, Tokairin T, Yoshida M, Ohi N, Nishimura T, Yamamoto Y, Li Q. 2004. Cell biology and pathology of liver sinusoidal endothelial cells. Med Electron Microsc. 37:208-215.
23. Fukasawa K, Fujii H, Saitoh Y, Koizumi K, Aozuka Y, Sekine K, Yamada M, Saiki I, Nishikawa K. 2006. Aminopeptidase N (APN/CD13) is selectively expressed in vascular endothelial cells and plays multiple roles in angiogenesis. Cancer Lett. 243:135-143.
24. Garde SV, Forté AJ, Ge M, Lepekhin EA, Panchal CJ, Rabbani SA, Wu JJ. 2007. Binding and internalization of NGRpeptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects. Anticancer Drugs. 18:1189-1200.
25. Gregorc V, Citterio G, Vitali G, Spreafico A, Scifo P, Borri A, Donadoni G, Rossoni G, Corti A, Caligaris-Cappio F, et al. 2010. Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours. Eur J Cancer. 46:198-206.
26. Gregorc V, Santoro A, Bennicelli E, Punt CJ, Citterio G, Timmer- Bonte JN, Caligaris Cappio F, Lambiase A, Bordignon C, van Herpen CM. 2009. Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours. Br J Cancer. 101:219-224.
27. Gregorc V, Zucali PA, Santoro A, Ceresoli GL, Citterio G, De Pas TM, Zilembo N, De Vincenzo F, Simonelli M, Rossoni G, et al. 2010. Phase II study of asparagine-glycine-argininehuman tumor necrosis factor {alpha}, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma. J Clin Oncol. 28:2604-2611.
28. Grifman M, Trepel M, Speece P, Gilbert LB, Arap W, Pasqualini R, Weitzman MD. 2001. Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids. Mol Ther. 3:964-975.
29. Hashida H, Takabayashi A, Kanai M, Adachi M, Kondo K, Kohno N, Yamaoka Y, Miyake M. 2002. Aminopeptidase N is involved in cell motility and angiogenesis: its clinical significance in human colon cancer. Gastroenterology. 122:376-386.
30. Ichimura E, Yamada M, Nishikawa K, Abe F, Nakajima T. 2006. Immunohistochemical expression of aminopeptidase N (CD13) in human lung squamous cell carcinomas, with special reference to Bestatin adjuvant therapy. Pathol Int. 56:296-300.
31. Ikeda N, Nakajima Y, Tokuhara T, Hattori N, Sho M, Kanehiro H, Miyake M. 2003. Clinical significance of aminopeptidase N/CD13 expression in human pancreatic carcinoma. Clin Cancer Res. 9:1503-1508.
32. Ito S, Miyahara R, Takahashi R, Nagai S, Takenaka K, Wada H, Tanaka F. 2009. Stromal aminopeptidase N expression: correlation with angiogenesis in non-small-cell lung cancer. Gen Thorac Cardiovasc Surg. 57:591-598.
33. Kawamura J, Shimada Y, Kitaichi H, Komoto I, Hashimoto Y, Kaganoi J, Miyake M, Yamasaki S, Kondo K, Imamura M. 2007. Clinicopathological significance of aminopeptidase N/CD13 expression in human gastric carcinoma. Hepatogastroenterology. 54:36-40. (Pubitemid 46511642)
34. Kunz J, Krause D, Kremer M, Dermietzel R. 1994. The 140-kDa protein of blood-brain barrier-associated pericytes is identical to aminopeptidase N. J Neurochem. 62:2375-2386.
35. Lee JS, Semela D, Iredale J, Shah VH. 2007. Sinusoidal remodeling and angiogenesis: a new function for the liver-specific pericyte? Hepatology. 45:817-825.
36. Liu L, Anderson WF, Beart RW, Gordon EM, Hall FL. 2000. Incorporation of tumor vasculature targeting motifs into moloney murine leukemia virus env escort proteins enhances retrovirus binding and transduction of human endothelial cells. J Virol. 74:5320-5328.
37. Look AT, Ashmun RA, Shapiro LH, Peiper SC. 1989. Human myeloid plasma membrane glycoprotein CD13 (gp150) is identical to aminopeptidase N. J Clin Invest. 83:1299-1307.
38. Luan Y, Wu W. 2007. The structure and main functions of aminopeptidase N. Curr Med Chem. 14:639-647.
39. Mahoney KM, Petrovic N, Schacke W, Shapiro LH. 2007. CD13/ APN transcription is regulated by the proto-oncogene c-Maf via an atypical response element. Gene. 403:178-187.
40. Mina-Osorio P. 2008. The moonlighting enzyme CD13: old and new functions to target. Trends Mol Med. 14:361-371.
41. O'Connel P, Gerkis V, D'Apice AJ. 1991. Variable O-glycosylation of CD13 (aminopeptidase N). J Biol Chem. 266:4593-4597.
42. Palmieri FE, Petrelli JJ, Ward PE. 1985. Vascular, plasma membrane aminopeptidase M: metabolism of vasoactive peptides. Biochem Pharmacol. 34:2309-2317.
43. Pasqualini R, Koivunen E, Kain R, Lahdenranta J, Sakamoto M, Stryhn A, Ashmun RA, Shapiro LH, Arap W, Ruoslahti E. 2000. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res. 60:722-727.
44. Pasqualini R, Ruoslahti E. 1996. Organ targeting in vivo using phage display peptide libraries. Nature. 380:364-366.
45. Pastorino F, Brignole C, Marimpietri D, Cilli M, Gambini C, Ribatti D, Longhi R, Allen TM, Corti A, Ponzoni M. 2003. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res. 63:7400-7409.
46. Piela-Smith TH, Korn JH. 1995. Aminopeptidase N: a constitutive cell-surface protein on human dermal fibroblasts. Cell Immunol. 162:42-48.
47. Rangel R, Sun Y, Guzman-Rojas L, Ozawa MG, Sun J, Giordano RJ, Van Pelt CS, Tinkey PT, Behringer RR, Sidman RL, et al. 2007. Impaired angiogenesis in aminopeptidase N-null mice. Proc Natl Acad Sci U S A. 104:4588-4593.
48. Razak K, Newland AC. 1992a. Induction of CD13 expression on fresh myeloid leukaemia: correlation of CD13 expression with aminopeptidase-N activity. Leuk Res. 16:625-630.
49. Razak K, Newland AC. 1992b. The significance of aminopeptidases and haematopoietic cell differentiation. Blood Rev. 6:243-250.
50. Riemann D, Kehlen A, Langner J. 1999. CD13 - not just a marker in leukemia typing. Immunol Today. 20:83-88.
51. Riemann D, Kehlen A, Thiele K, Lohn M, Langner J. 1997. Induction of aminopeptidase N/CD13 on human lymphocytes after adhesion to fibroblast-like synoviocytes, endothelial cells, epithelial cells, and monocytes/macrophages. J Immunol. 158:3425-3432.
52. Rocken C, Licht J, Roessner A, Carl-McGrath S. 2005. Canalicular immunostaining of aminopeptidase N (CD13) as a diagnostic marker for hepatocellular carcinoma. J Clin Pathol. 58:1069-1075.
53. Santoro A, Pressiani T, Citterio G, Rossoni G, Donadoni G, Pozzi F, Rimassa L, Personeni N, Bozzarelli S, Rossoni G, et al. 2010. Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma. Br J Cancer. 103:837-844.
54. Santoro A, Rimassa L, Sobrero AF, Citterio G, Sclafani F, Carnaghi C, Pessino A, Caprioni F, Andretta V, Tronconi M, et al. 2010. Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy. Eur J Cancer. 46:2746-2752.
55. Surowiak P, Drag M, Materna V, Suchocki S, Grzywa R, Spaczynski M, Dietel M, Oleksyszyn J, Zabel M, Lage H. 2006. Expression of aminopeptidase N/CD13 in human ovarian cancers. Int J Gynecol Cancer. 16:1783-1788.
56. Taylor A. 1993. Aminopeptidases: structure and function. FASEB J. 7:290-298.
57. Terauchi M, Kajiyama H, Shibata K, Ino K, Nawa A, Mizutani S, Kikkawa F. 2007. Inhibition of APN/CD13 leads to suppressed progressive potentila in ovarian carcinoma cells. BMC Cancer. 7:140.
58. Tokuhara T, Hattori N, Ishida H, Hirai T, Higashiyama M, Kodama K, Miyake M. 2006. Clinical significance of aminopeptidase N in non-small cell lung cancer. Clin Cancer Res. 12:3971-3978.
59. Tsukamoto H, Shibata K, Kajiyama H, Terauchi M, Nawa A, Kikkawa F. 2008. Aminopeptidase N (APN)/CD13 inhibitor, Ubenimex, enhances radiation sensitivity in human cervical cancer. BMC Cancer. 8:74.
60. van Laarhoven HW, Fiedler W, Desar IM, van Asten JJ, Marreaud S, Lacombe D, Govaerts AS, Bogaerts J, Lasch P, Timmer- Bonte JN, et al. 2010. Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041). Clin Cancer Res. 16:1315-1323.
61. Wulfaenger J, Niedling S, Riemann D, Seliger B. 2008. Aminopeptidase N (APN)/CD13-dependent CXCR4 downregulation is associated with diminished cell migration, proliferation and invasion. Mol Membr Biol. 25:72-82.
62. Yamashita M, Kajiyama H, Terauchi M, Shibata K, Ino K, Nawa A, Mizutani S, Kikkawa F. 2007. Involvement of aminopeptidase N in enhanced chemosensitivity to paclitaxel in ovarian carcinoma in vitro and in vivo. Int J Cancer. 120:2243-2250.
63. Yang E, Shim JS, Woo HJ, Kim KW, Kwon HJ. 2007. Aminopeptidase N/CD13 induces angiogenesis through interaction with a pro-angiogenic protein, galectin-3. Biochem Biophys Res Commun. 363:336-341.